ClinicalTrials.gg
Active, not recruitingNCT06903065Updated Oct 8, 2026

A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis

A Phase 1 interventional study of RO7790121 in MASH, sponsored by Hoffmann-La Roche. Active, not recruiting at 15 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Updated Oct 8, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.

02

Conditions studied

  • MASH
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • within the range of >= 25 and \<=45 kilograms per square meter (kg/m\^2)
  • MASH with fibrosis score of F3 or F4 confirmed by transient elastography measurement >=12.0 kPa and \<=25.0 kPa
  • Agreement to adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  • Weight gain or loss >5% in the 3 months prior to baseline or >10% in the 6 months prior to baseline
  • Bariatric surgery within 1 year prior to baseline
  • Current signs or prior history of decompensated liver disease
  • Complications or clinical evidence of portal hypertension
  • Lack of peripheral venous access
  • Other causes of liver disease based on medical history and/or centralized review of liver histology
  • History of liver transplantation
  • Current or prior history of hepatocellular carcinoma (HCC)
  • Uncontrolled hypertension
  • Concomitant Type 1 diabetes, or Type 2 diabetes with >10%
  • History of within 5 years prior to screening, with the exception of malignancies with a negligible risk of or death
  • Current, significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 1 year prior to screening
  • Initiation of a medication of an antidiabetic, weight loss, lipid-modifying or anti-depressant drug class
  • Active tuberculosis requiring treatment within the 12 months prior to baseline
  • History of organ transplant
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    RO7790121

    Particiapants will receive RO7790121 via intravenous (IV) infusion followed by subcutaneous (SC) injections.

    Drug: RO7790121

Interventions

  • Participants will be administered RO7790121 via IV infusion on Day 1, and Weeks 2, 6 and 10. Participants will then be administered RO7790121 SC injections every four weeks (Q4W) from week 14 up to and including Week 50.

    Also known as: PF-06480605, RVT-3101, RG6631

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events (AEs)

    Time frame: Up to Week 52 after Baseline

Secondary outcomes

  1. Change from Baseline in Liver Stiffness

    Liver stiffness will be measured by transient elastography (FibroScan® or FibroTouch®) and indicated in kilopascals (kPa).

    Time frame: Baseline to Week 52

  2. Change from Baseline in Serum Levels of Propeptide of Type lll Collagen (Pro-C3)

    Time frame: Baseline to Week 52

  3. Change from Baseline in Serum Enhanced Liver Fibrosis (ELF) Test

    Time frame: Baseline to Week 52

  4. Change from Baseline in Fibro-inflammation

    Fibro-inflammation will be measured using magnetic resonance imaging iron-corrected T1 mapping (MRI cT1).

    Time frame: Baseline to Weeks 52

  5. Pre-dose Concentrations of RO7790121

    Time frame: Weeks 0, 2, 6, 10, 14, 26, and 38

  6. Maximum Concentration (Cmax) of RO7790121

    Time frame: Weeks 0, 2, 6, 10, 52 and 62

  7. Minimum Concentration (Cmin) of RO7790121

    Time frame: Weeks 0, 2, 6, 10, 52 and 62

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2025 to primary completion in Sep 2026, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 30, 2025
StartActual
Apr 14, 2025
Primary completionActual
Sep 24, 2026
CompletionEst.
Dec 3, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 30, 2026→Sep 24, 2026 (actual)
Oct 8, 2026
Study completion
Dec 30, 2026→Dec 3, 2026
Oct 8, 2026
Enrollment
50 (estimated)→56 (actual)
Oct 8, 2026
Show all 2 updates
  1. Oct 8, 2026
    Primary completion Sep 30, 2026→Sep 24, 2026 (now actual)
    Study completion Dec 30, 2026→Dec 3, 2026
    Enrollment 50 (estimated)→56 (actual)
    + 1 other change: verification date
  2. Sep 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06903065
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 30, 2025
Start date
Apr 14, 2025
Primary completion
Sep 24, 2026
Completion
Dec 3, 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion